---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-084154"
form_type: "8-K"
ticker: "EYPT"
cik: "0001314102"
company_name: "EyePoint, Inc."
filed_at: "2026-03-02T23:59:59+00:00"
generated_at: "2026-05-15T22:33:37.937772+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# EyePoint doses first patients in Phase 3 DME trials for DURAVYU; topline data 2H 2027

## Summary
- First patients dosed in global Phase 3 COMO and CAPRI trials of DURAVYU (vorolanib intravitreal insert) for diabetic macular edema.
- DURAVYU is a sustained-release TKI inhibiting VEGF, PDGF, and IL-6; design based on positive Phase 2 VERONA results.
- Non-inferiority trials vs aflibercept; ~240 patients each; primary endpoint BCVA change at weeks 52 and 56.
- DURAVYU 2.7mg administered via standard intravitreal injection every six months; topline data anticipated 2H 2027.
- Program aligns with FDA and EMA after End of Phase 2 meeting; aims to reduce treatment burden for DME patients.

## SEC filing metadata
- accession: 0001193125-26-084154
- form_type: 8-K
- ticker: EYPT
- cik: 0001314102
- company_name: EyePoint, Inc.
- filed_at: 2026-03-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1314102/000119312526084154/0001193125-26-084154-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1314102/000119312526084154/eypt-20260226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-084154
- JSON: https://secwatch.observer/filing/0001193125-26-084154.json
- Plain text: https://secwatch.observer/filing/0001193125-26-084154.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.